Pharmafile Logo

Viltolarsen

- PMLiVE

FDA approves Sarepta rival NS Pharma’s Duchenne drug

Drug approved for patients with exon 53 mutation

- PMLiVE

FDA sets Q3 decision date for NS Pharma’s DMD drug

If approved it will become second-to-market after Sarepta

- PMLiVE

Sarepta rival NS Pharma files Duchenne drug with FDA

Another blow for Sarepta following FDA rejection earlier this year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links